Even if the ctDNA mutation VAF has been previously associated with tumor load and metastatic burden,20 pretreatment levels of detectable KRAS G12C–mutant ctDNA were associated with neither tumor response nor survival outcomes under sotorasib therapy. The gene discussed is KRAS; the disease is neoplasm.